{
  "drug_name": "Moxifloxacin",
  "tradename": "Avelox",
  "usage_and_dosing": {
    "general": [
      "Moxifloxacin is a fluoroquinolone with enhanced activity against respiratory pathogens, including atypical organisms and S. pneumoniae. It is also active against many anaerobic bacteria.",
      "Not active vs. P. aeruginosa.",
      "FDA-approved for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections, and complicated intra-abdominal infections.",
      "For class-wide adverse effects, see Fluoroquinolones, Overview."
    ],
    "adult_dose": {
      "usual_dose": "400 mg po/IV q24h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "12",
    "half_life_esrd": "No data",
    "dose_renal_function_normal": "400 mg po/IV q24h",
    "crcl_or_egfr": "No dosage adjustment",
    "hemodialysis": "No dosage adjustment",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "For complete class-wide adverse effects see Fluoroquinolones, Overview and for QTc prolongation, see QTc Interval Prolongation.",
    "Any of the fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",
    "lactation": "Short-term use safe, monitor infant for GI toxicity; avoid if possible.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (400 mg), Injection",
    "food_recommendation": "Tab ± food",
    "oral_absorption_percent": "90",
    "tmax_hr": "1-2",
    "peak_serum_conc_ug_ml": "3.1 (400 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "40-50",
    "volume_of_distribution_vd_l_kg_vss": "1.7-2.7 L/kg (Vss)",
    "avg_serum_half_life_hr": "12",
    "elimination": "Hepatic (50%), renal (50%)",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "17-20",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "36.3 (400 mg po, 0-24h)"
  },
  "major_drug_interactions": [
      {"drug": "Antacids (Al, Mg)", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"},
      {"drug": "Antiarrhythmics (Class IA/III)", "effect": "↑ QT interval", "management": "Avoid co-administration"},
      {"drug": "Calcium supplements", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"},
      {"drug": "Didanosine", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"},
      {"drug": "Iron supplements", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"},
      {"drug": "NSAIDS", "effect": "↑ risk of CNS stimulation/seizures", "management": "Monitor or avoid"},
      {"drug": "Oral hypoglycemics", "effect": "↑↓ blood glucose", "management": "Monitor"},
      {"drug": "Probenecid", "effect": "↑ moxifloxacin", "management": "Monitor or avoid"},
      {"drug": "Sucralfate", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"},
      {"drug": "Warfarin", "effect": "↑ INR", "management": "Monitor INR, adjust dosage"},
      {"drug": "Zinc", "effect": "↓ moxifloxacin", "management": "Separate administration by 4 hours"}
  ]
}
